Patent: 9,284,370
✉ Email this page to a colleague
Summary for Patent: 9,284,370
Title: | Methods for treating juvenile idiopathic arthritis |
Abstract: | The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNF.alpha. inhibitor, such as a human TNF.alpha. antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNF.alpha. inhibitor. |
Inventor(s): | Medich; John R. (Highland Park, IL), Paulson; Susan K. (Downers Grove, IL), Noertersheuser; Peter A. (Gro-Karlbach, DE) |
Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 14/679,476 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,284,370 |
Patent Claims: | see list of patent claims |
Details for Patent 9,284,370
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2027-06-11 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2027-06-11 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2027-06-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |